Constraints in acquiring and utilizing directors' experience: An empirical study of new-market entry in the pharmaceutical industry

2014 ◽  
Vol 36 (3) ◽  
pp. 339-359 ◽  
Author(s):  
Luis Diestre ◽  
Nandini Rajagopalan ◽  
Shantanu Dutta
Author(s):  
Enrico Böhme ◽  
Jonas Severin Frank ◽  
Wolfgang Kerber

AbstractIn this paper, we show that a provision in antitrust law to allow patent settlements with a later market entry of generics than the date that is expected under patent litigation can increase consumer welfare. We introduce a policy parameter for determining the optimal additional period for collusion that would incentivize the challenging of weak patents and maximize consumer welfare. While in principle, later market entry leads to higher profits and lower consumer welfare, this can be more than compensated for if more patents are challenged as a result.


Author(s):  
Jingyuan Zhao

The Chinese pharmaceutical market has become the world's second largest market. The Chinese pharmaceutical industry is becoming a growing player in global pharmaceutical chain. This chapter aims to solve following issues: the market orientation and resource base of Chinese pharmaceutical industry, the role in the global pharmaceutical industrial chain, and the international market entry modes of Chinese pharmaceutical companies. The sample companies are selected and surveyed with a focus on the international market entry modes. Through an empirical research, this chapter summarizes the experience of Chinese pharmaceutical internationalization and finds the effective modes of international market entry are product upgrading along the industrial chain, international certification and cooperation, outsourcing and licensing, and other paths of overseas expansion. The implication for pharmaceutical companies of emerging markets is to choose the suitable entry modes based on advantages, learn from the experience of other emerging markets and domestic leading companies of internationalization, and gradually enter the standard market. This study not only provides international market entry modes for the latecomer of Chinese pharmaceutical companies but also enriches the internationalization theory of emerging markets.


Sign in / Sign up

Export Citation Format

Share Document